Literature DB >> 14716029

Cytoplasmic expression of EGFP in dendritic cells transfected with in vitro transcribed mRNA or cellular total RNA extracted from EGFP expressing leukemia cells.

Masuhiro Takahashi1, Miwako Narita, Flavio Ayres, Naoko Satoh, Takashi Abe, Toshio Yanao, Tatsuo Furukawa, Ken Toba, Takeshi Hirohashi, Yoshifusa Aizawa.   

Abstract

The present study was designed for identifying the protein synthesis in cytoplasm of dendritic cells transfected with in vitro transcribed mRNA and cellular total RNA extracted from tumor cells. Dendritic cells were generated from cord blood-CD34+ cells by culture with GM-CSF, SCF, and TNF-alpha, or from peripheral blood adherent cells or CD14+ cells by culture with GM-CSF and IL-4. Dendritic cells were transfected with in vitro transcribed EGFP mRNA or cellular total RNA, which was isolated from EGFP expressing K562, by electroporation using a square-wave pulse. Optimal in vitro transcribed EGFP mRNA transfection efficiency (>90%) was observed in a single electroporation of 1.75 kV/cm (electric field strength) with a pulse width of 250 micros. Although the intensity of EGFP expression in dendritic cells transfected with cellular total RNA was less compared with that in dendritic cells transfected with in vitro transcribed EGFP mRNA, a definite cytoplasmic synthesis of EGFP was demonstrated in dendritic cells transfected with cellular total RNA. The visual identification of cytoplasmic expression of cellular total RNA in dendritic cells revealed that electroporation of tumor cell-derived RNA could be a useful tool to load dendritic cells with tumor antigens for establishing an efficient dendritic cell-based tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14716029     DOI: 10.1385/MO:20:4:335

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

Review 1.  Emerging clinical applications of RNA.

Authors:  Bruce A Sullenger; Eli Gilboa
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

2.  Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

Authors:  D Boczkowski; S K Nair; J H Nam; H K Lyerly; E Gilboa
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

Authors:  S K Nair; D Boczkowski; M Morse; R I Cumming; H K Lyerly; E Gilboa
Journal:  Nat Biotechnol       Date:  1998-04       Impact factor: 54.908

4.  Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.

Authors:  A Heiser; M A Maurice; D R Yancey; D M Coleman; P Dahm; J Vieweg
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

5.  mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT).

Authors:  Stein Saebøe-Larssen; Ellen Fossberg; Gustav Gaudernack
Journal:  J Immunol Methods       Date:  2002-01-01       Impact factor: 2.303

6.  Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.

Authors:  A Heiser; P Dahm; D R Yancey; M A Maurice; D Boczkowski; S K Nair; E Gilboa; J Vieweg
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

7.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

Authors:  S K Nair; A Heiser; D Boczkowski; A Majumdar; M Naoe; J S Lebkowski; J Vieweg; E Gilboa
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

8.  Effects of transfection of p210bcr-abl and bcr-v-abl into the factor-dependent human leukemia cell line HSM-911.

Authors:  M Takahashi; N Shigeno; H Takahashi; N Suzuki; M Masuko; K Nikkuni; K Toba; T Furukawa; S Aoki; K Kishi; T Koike; Y Aizawa
Journal:  Leuk Res       Date:  1997 Nov-Dec       Impact factor: 3.156

9.  Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.

Authors:  Matthew F Kalady; Mark W Onaitis; Karen M Padilla; Sirisha Emani; Douglas S Tyler; Scott K Pruitt
Journal:  J Surg Res       Date:  2002-06-01       Impact factor: 2.192

10.  Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.

Authors:  D M Ashley; B Faiola; S Nair; L P Hale; D D Bigner; E Gilboa
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

View more
  4 in total

1.  Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA.

Authors:  Miwako Narita; Nozomi Tochiki; Anri Saitoh; Norihiro Watanabe; Masami Kaji; Noriyuki Satoh; Akie Yamahira; Takeshi Nakamura; Masayoshi Masuko; Tatsuo Furukawa; Ken Toba; Ichiro Fuse; Yoshifusa Aizawa; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2008-12-05       Impact factor: 3.064

2.  Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.

Authors:  Anri Saitoh; Miwako Narita; Norihiro Watanabe; Nozomi Tochiki; Noriyuki Satoh; Jun Takizawa; Tatsuo Furukawa; Ken Toba; Yoshifusa Aizawa; Shohji Shinada; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2007-09-11       Impact factor: 3.064

3.  Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response.

Authors:  Jacoba G Slagter-Jäger; Alexa Raney; Whitney E Lewis; Mark A Debenedette; Charles A Nicolette; Irina Y Tcherepanova
Journal:  Mol Ther Nucleic Acids       Date:  2013-05-07       Impact factor: 10.183

4.  Cellular Processes Involved in Jurkat Cells Exposed to Nanosecond Pulsed Electric Field.

Authors:  Huijuan Li; Shibin Liu; Xue Yang; Yongqian Du; Jiezhang Luo; Jie Tan; Yulong Sun
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.